Apalutamide news

All news on Apalutamide (also known as Erleada): plants, production capacities, investments and involved companies.

31 May 2026

Johnson & Johnson PROTEUS Phase 3: Perioperative ERLEADA reduces risk of metastasis or death by 20%

Perioperative apalutamide + ADT (6 months pre/post-surgery) raised pCR/MRD to 8.9% vs 1%, delayed need for further therapy >6 vs 3.5 years, met dual primary endpoints; safety profile as expected.
2 February 2026

Johnson & Johnson: ERLEADA® reduces death risk by 51% in mCSPC patients vs. darolutamide

Real-world study shows ERLEADA® offers significant survival benefits for mCSPC patients without docetaxel, supporting its use as a standard treatment.

Who will be producing Apalutamide in the future?

Find out with chemXplore Alpha

Learn more